Phenylephrine Hydrochloride - Lifestar Pharma LLC | Mankind Pharma Limited

Manufacturer
Lifestar Pharma LLC | Mankind Pharma Limited
Effective date
2026-07-30
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
7
Source
daily-update
Hydrated at
2026-08-04 03:37:18

Label at a glance#

ProductPhenylephrine Hydrochloride
Active ingredientPHENYLEPHRINE HYDROCHLORIDE
Label structure15 sections

Indications and uses

Phenylephrine Hydrochloride Ophthalmic Solution, USP 10%, is indicated to dilate the pupil.

Dosage and administration

In patients 1 year of age or greater, apply one drop of either phenylephrine hydrochloride ophthalmic solution 2.5% or 10% every 3 to 5 minutes to the conjunctival fornix as required up to a maximum of 3 drops per eye per day In order to obtain a greater degree of mydriasis, phenylephrine hydrochloride ophthalmic solution 10% may be needed In pediatric patients less than 1 year of age, one drop of phenylephrine hy...

Storage and handling

Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is supplied as a sterile, clear, colorless to yellow color, aqueous, topical ophthalmic solution in an opaque, white low density polyethylene (LDPE) bottle with a natural LDPE dropper tip and red cap in the following sizes: NDC 70756-614-30         5 mL in 10 mL bottle After opening, Phenylephrine Hydrochloride Ophthalmic Solution, USP can be used until the ...

Label contents#

Full prescribing information#

1 INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Phenylephrine Hydrochloride Ophthalmic Solution, USP 10%, is indicated to dilate the pupil.

2 DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

2.1 General Dosing Recommendations

In patients 1 year of age or greater, apply one drop of either phenylephrine hydrochloride ophthalmic solution 2.5% or 10% every 3 to 5 minutes to the conjunctival fornix as required up to a maximum of 3 drops per eye per day

In order to obtain a greater degree of mydriasis, phenylephrine hydrochloride ophthalmic solution 10% may be needed

2.2 Dosing in Pediatric Patients Less Than 1 Year of Age

In pediatric patients less than 1 year of age, one drop of phenylephrine hydrochloride ophthalmic solution 2.5% should be instilled at 3 to 5 minute intervals up to a maximum of 3 drops per eye.

3 DOSAGE FORMS AND STRENGTHS

DOSAGE FORMS & STRENGTHS SECTION

Phenylephrine hydrochloride ophthalmic solution, USP 10% is a clear, colorless, to yellow colored sterile topical ophthalmic solution containing phenylephrine hydrochloride 10%.: each mL contains 100 mg of phenylephrine hydrochloride.

4 CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

4.1 Cardiac and Endocrine Disease

Phenylephrine hydrochloride ophthalmic solution 10% is contraindicated in patients with hypertension or thyrotoxicosis. Phenylephrine hydrochloride ophthalmic solution 2.5% should be used in these patients.

4.2 Pediatric Patients Less Than 1 Year of Age

Phenylephrine hydrochloride ophthalmic solution 10% is contraindicated in pediatric patients less than 1 year of age due to the increased risk of systemic toxicity. Phenylephrine hydrochloride ophthalmic solution 2.5% should be used in these patients [See Dosage and Administration (2.2)].

5 WARNINGS AND PRECAUTIONS

WARNINGS AND PRECAUTIONS SECTION

5.1 Topical Ophthalmic Use Only

Phenylephrine hydrochloride ophthalmic solution 10% is not indicated for injection.

5.2 Cardiovascular Reactions

There have been reports of serious cardiovascular reactions, including ventricular arrhythmias and myocardial infarctions, in patients using phenylephrine 10%. These episodes, some fatal, have usually occurred in patients with pre-existing cardiovascular diseases. Phenylephrine Hydrochloride Ophthalmic Solution, USP 2.5% should be used in these patients.

5.3 Elevation of Blood Pressure

A significant elevation in blood pressure is not common but has been reported following conjunctival instillation of recommended doses of phenylephrine 10%. The risk is less with phenylephrine 2.5%. Caution should be exercised with the use of phenylephrine 10% in pediatric patients less than 5 years of age and patients with hyperthyroidism, or cardiovascular disease. The post-treatment blood pressure of patients with cardiac and endocrine diseases and any patients who develop symptoms should be carefully monitored.

5.4 Rebound Miosis

Rebound miosis has been reported one day after receiving phenylephrine hydrochloride ophthalmic solution, and re-instillation of the drug produced a lesser mydriatic effect.

6 ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

The following serious adverse reactions are described below and elsewhere in the labeling:

The following adverse reactions have been identified following use of phenylephrine hydrochloride ophthalmic solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

6.1 Ocular Adverse Reactions

Eye pain and stinging on instillation, temporary blurred vision and photophobia, and conjunctival sensitization may occur.

6.2 Systemic Adverse Reactions

A marked increase in blood pressure has been reported particularly, but not limited to low weight premature neonates, infants and hypertensive patients.

Cardiovascular effects which have been seen primarily in hypertensive patients following topical ocular use of phenylephrine hydrochloride ophthalmic solution 10% include marked increase in blood pressure, syncope, myocardial infarction, tachycardia, arrhythmia and subarachnoid hemorrhage [See Warnings and Precautions (5.2 and 5.3 )].

7 DRUG INTERACTIONS

DRUG INTERACTIONS SECTION

7.1 Agents That May Exaggerate Pressor Responses

Concomitant use of phenylephrine and atropine may enhance the pressor effects and induce tachycardia in some patients. Phenylephrine may potentiate the cardiovascular depressant effects of some inhalation anesthetic agents.

8 USE IN SPECIFIC POPULATIONS

USE IN SPECIFIC POPULATIONS SECTION

8.1 Pregnancy

PREGNANCY SECTION

Animal reproduction studies have not been conducted with topical phenylephrine. It is also not known whether phenylephrine can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Phenylephrine hydrochloride should be given to a pregnant woman only if clearly needed.

8.3 Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human breast milk. Because many drugs are excreted in human milk, caution should be exercised when phenylephrine hydrochloride ophthalmic solution 2.5% and 10% is administered to a nursing woman.

8.4 Pediatric Use

PEDIATRIC USE SECTION

Phenylephrine hydrochloride ophthalmic solution 10% is contraindicated in pediatric patients less than 1 year of age [See Contraindications (4.2) ].

8.5 Geriatric Use

GERIATRIC USE SECTION

No overall differences in safety and effectiveness have been observed between elderly and younger adult patients.

10 OVERDOSAGE

OVERDOSAGE SECTION

Overdosage of phenylephrine may cause a rapid rise in blood pressure. It may also cause headache, anxiety, nausea, and vomiting, and ventricular arrhythmias. Prompt injection of a rapidly acting alpha-adrenergic blocking agent such as phentolamine has been recommended.

11 DESCRIPTION

DESCRIPTION SECTION

Phenylephrine Hydrochloride Ophthalmic Solution, USP is a sterile, clear, colorless to yellow color solution, topical α -adrenergic agonist for ophthalmic use. The active ingredient is represented by the chemical structure

Chemical Structure
Chemical Structure

Chemical Name: (R)-3-hydroxy-α[(methylamino)methyl]benzenemethanol hydrochloride.

Molecular Formula: C9H13NO2.HCl

Molecular Weight: 203.67 g/mol

Each mL of Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% contains: ACTIVE: Phenylephrine Hydrochloride 100 mg (10%); INACTIVES: Sodium Phosphate Monobasic, Sodium Phosphate Dibasic, Water for Injection. Phosphoric Acid and/or Sodium Hydroxide may be added to adjust pH (4.0 to 7.5). The solution has a tonicity of 985 mOsm/kg; PRESERVATIVE: Benzalkonium Chloride 0.1 mg (0.01%).

12 CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

12.1 Mechanism of Action

MECHANISM OF ACTION SECTION

Phenylephrine hydrochloride is an α-1 adrenergic agonist drug that is used in ophthalmology mainly for its mydriatic effect. After topical application to the conjunctiva, phenylephrine acts directly on α-adrenergic receptors in the eye, producing contraction of the dilator muscle of the pupil and constriction of the arterioles in the conjunctiva.

12.2 Pharmacodynamics

PHARMACODYNAMICS SECTION

Maximal mydriasis occurs in 20 to 90 minutes with recovery after 3 to 8 hours.

Systemic absorption of sufficient quantities of phenylephrine may lead to systemic α-adrenergic effects, such as rise in blood pressure which may be accompanied by a reflex atropine-sensitive bradycardia.

12.3 Pharmacokinetics

PHARMACOKINETICS SECTION

The systemic exposure following topical administration of phenylephrine hydrochloride ophthalmic solution has not been studied. A higher systemic absorption is expected for the 10% solution than the 2.5% solution and when the corneal barrier function is compromised.

14 CLINICAL STUDIES

CLINICAL STUDIES SECTION

Pupillary dilation following topical administration of phenylephrine hydrochloride ophthalmic solution has been demonstrated in controlled clinical studies in adults and pediatric patients with different levels of iris pigmentation. Pupil movement is generally seen within 15 minutes, maximal mydriasis between 20 to 90 minutes and recovery after 3 to 8 hours. Darker irides tend to dilate slower than lighter irides.

16 HOW SUPPLIED/STORAGE AND HANDLING

HOW SUPPLIED SECTION

Phenylephrine Hydrochloride Ophthalmic Solution, USP 10% is supplied as a sterile, clear, colorless to yellow color, aqueous, topical ophthalmic solution in an opaque, white low density polyethylene (LDPE) bottle with a natural LDPE dropper tip and red cap in the following sizes:

NDC 70756-614-30         5 mL in 10 mL bottle

After opening, Phenylephrine Hydrochloride Ophthalmic Solution, USP can be used until the expiration date on the bottle.

STORAGE AND HANDLING SECTION

Storage: Store at 20° to 25°C (68° to 77°F). See USP Controlled room temperature. Keep container tightly closed. Protect from light and excessive heat.

Do not use if solution is brown or contains precipitate.

17 PATIENT COUNSELING INFORMATION

INFORMATION FOR PATIENTS SECTION

Advise patients not to touch the dropper tip to any surface as this may contaminate the solution. Inform patients that they may experience sensitivity to light and should protect their eyes in bright illumination while their pupils are dilated.

Manufactured for:

Lifestar Pharma LLC

1200 MacArthur Blvd.

Mahwah, NJ 07430 USA

Made in India

Revised: March 2023, V-04

Manufactured for:

Lifestar Pharma LLC

1200 MacArthur Blvd.

Mahwah, NJ 07430 USA

Product of Taiwan

Revised: April 2026, V-01

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Made in India

NDC 70756-614-30

Phenylephrine Hydrochloride

Ophthalmic

Solution, USP

10%

For Topical Application in the Eye.

Not for Injection

Rx only

5 mL

5ml-label
5ml-label

NDC 70756-614-30

Phenylephrine

Hydrochloride Ophthalmic

Solution, USP

10%

For Topical Application in the Eye.

Not for Injection

Rx only

5 mL

5ml-carton
5ml-carton

Product of Taiwan

NDC 70756-614-30

Phenylephrine Hydrochloride

Ophthalmic

Solution, USP

10%

For Topical Application in the Eye.

Not for Injection

Rx only

5 mL

5ml-label-taiwan
5ml-label-taiwan

NDC 70756-614-30

Phenylephrine Hydrochloride

Ophthalmic

Solution, USP

10%

For Topical Application in the Eye.

Not for Injection

Rx only

5 mL

5ml-carton-taiwan
5ml-carton-taiwan

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
BarcodeEAN-130370756614302GTIN-13: 0370756614302
EAN-13: 0370756614302
GTIN-12: 370756614302
UPC-A: 370756614302
GTIN storage (14 digits): 00370756614302
1cc4ae4f-b3bb-4902-9725-1504f5f199ac-04.jpg, 1cc4ae4f-b3bb-4902-9725-1504f5f199ac-02.jpg, 1cc4ae4f-b3bb-4902-9725-1504f5f199ac-05.jpg, 1cc4ae4f-b3bb-4902-9725-1504f5f199ac-03.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e4e263da-1c53-440f-bb80-b7a575843b5aProduct name120260313
d2168cac-a261-415a-9c78-3522859fa720Product name320251124
726062af-1135-4707-a1d7-57256991bbf9Product name220250226
05a8cdd1-eeb8-409e-b938-0778225eca7dProduct name420250221
e5b5c132-b15d-435b-9faa-2f74e5cadcf9Product name820250220
f489e8f3-5c9e-4818-b539-a73587edcfc7Product name220240229
0f7ae452-206d-4fc4-868d-56fc47074084Product name120231011
b5abe2e3-39a1-43eb-9bff-f3c1653fe3dfProduct name220190930
e0b6c8be-f2bd-9f86-a9fc-3ed56ffaa814Product name320150910
19c71a3d-ed9c-166b-a7e5-38c250c35631Product name120140508
42f3c020-f1b3-89bc-7bdc-e1f10e680485Product name120140508
e949165d-714d-e548-2b76-0cb5def16f30Product name120140508

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
70756-614-30ML - Milliliter70756-6149088007f-32ea-4b74-9493-d4d9748ad4ca12023-02-06

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70756-61470756-614-30

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

Older Hydrated Versions#

Version, Effective date, Source table
VersionEffective dateSourceHydrated
52023-05-19full-release2026-05-31 20:49:28

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A216496-001PHENYLEPHRINE HYDROCHLORIDEPHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A216496-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11d4dbc9d85df4…
2026-10-15 13:18:302026-09A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11c2088c7a36db…
2026-09-14 22:38:342026-08A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-1184e616aacf4f…
2026-08-18 06:07:402026-07A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-1131067a03dcf5…
2025-08-23 18:47 UTC2025-08A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-116a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-1103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-112680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-115bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-1179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-111e350fbaab3a…
2024-05-31 18:47 UTC2024-05A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-118072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-116a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-111c564ffb4f44…
2023-12-20 04:57 UTC2023-12A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-119b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICAT2023-01-11a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICAT2023-01-113f0d92c62455…
2023-05-13 08:27 UTC2023-05A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICAT2023-01-11053a50430f4f…
2023-01-26 05:58 UTC2023-01A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICAT2023-01-113bdfa0b2c4d7…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A216496-001PHENYLEPHRINE HYDROCHLORIDE10%SOLUTION/DROPS / OPHTHALMICATRS2023-01-11a50c72e98297…

Observed Orange Book normalized TE history#

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10A216496-001AT1d4dbc9d85df4…
2026-10-15 13:18:302026-09A216496-001AT1c2088c7a36db…
2026-09-14 22:38:342026-08A216496-001AT184e616aacf4f…
2026-08-18 06:07:402026-07A216496-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A216496-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A216496-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08A216496-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A216496-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A216496-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A216496-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A216496-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A216496-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A216496-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A216496-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A216496-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A216496-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A216496-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A216496-001AT18072bd15b7f6…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A216496-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A216496-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A216496-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A216496-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A216496-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A216496-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A216496-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05A216496-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01A216496-001AT13bdfa0b2c4d7…
2026-07-26 02:55 UTC · 3 captures of this ZIP2026-06A216496-001AT1a50c72e98297…

Observed Orange Book exclusivity history#

Captured, Edition, Application-product table
CapturedEditionApplication-productExclusivity codeExpirationSource SHA-256
2023-12-20 04:57 UTC2023-12A216496-001CGT2023-07-17ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A216496-001CGT2023-07-17a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A216496-001CGT2023-07-179b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A216496-001CGT2023-07-17a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A216496-001CGT2023-07-173f0d92c62455…
2023-05-13 08:27 UTC2023-05A216496-001CGT2023-07-17053a50430f4f…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Phenylephrine HydrochloridePHENYLEPHRINE HYDROCHLORIDELifestar Pharma LLC1767c4b7-36a0-4e64-9091-2af22161402f2026-07-30Warnings, Adverse reactionsExact identifier
ndc (package): 70756-614-30
ndc (product): 70756-614
ndc11 (package): 70756061430
spl id: 1cc4ae4f-b3bb-4902-9725-1504f5f199ac
spl set id: 1767c4b7-36a0-4e64-9091-2af22161402f

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.